Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | APOBEC3G | Q9HC16 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | XPO1 | O14980 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL512955 | 0.82 | LMNA (0.63) | RAB9AL3MBTL1ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL2619292 | 0.81 | SMN1; SMN2 (0.68) | RAB9AL3MBTL1ALDH1A1HPGDATM | |
| SCHEMBL4405908 | 0.78 | RAB9A (0.61) | RAB9AL3MBTL1ALDH1A1HPGDATM | |
| SCHEMBL23625644 | 0.77 | RAB9A (0.65) | RAB9AL3MBTL1ALDH1A1CYP1A2CYP2D6 | |
| SCHEMBL4407341 | 0.76 | TRPV1 (0.59) | RAB9AL3MBTL1ALDH1A1HPGDATM | |
| SCHEMBL4412228 | 0.76 | RAB9A (0.59) | RAB9AL3MBTL1ALDH1A1HPGDATM | |
| SCHEMBL4413466 | 0.76 | RAB9A (1.00) | RAB9AL3MBTL1ALDH1A1HPGDATM | |
| SCHEMBL23625631 | 0.76 | RAB9A (0.62) | RAB9AL3MBTL1ALDH1A1CYP1A2CYP2D6 | |
| SCHEMBL4411938 | 0.75 | RAB9A (0.57) | RAB9AL3MBTL1ALDH1A1CYP1A2CYP2D6 | |
| SCHEMBL27810679 | 0.74 | RAB9A (0.61) | RAB9AL3MBTL1ALDH1A1HPGDATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2477981-A1 | HETEROCYCLIC MGLU5 ANTAGONISTS | Recordati Ireland Limited (IE) | 2012-07-25 | — | — | EP | disclosed |
| US-20120028931-A1 | HETEROCYCLIC M-GLU5 ANTAGONISTS | RECORDATI IRELAND LIMITED (IE) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028931-A1 | HETEROCYCLIC M-GLU5 ANTAGONISTS | OPRM1, GRM5, OPRD1 | RAB9A 2058/4885L3MBTL1 1294/4885ALDH1A1 2610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.